take time nu right pt
thursday volitionrx announc earn provid busi updat
compani continu transit discovery-grad commercial-grad nu
product delay develop timelin key program includ
european colorect cancer nu triag screen product month
rel previou project howev support manag decis
defer valid studi commercial-grad optim complet
await initi valid studi believ volitionrx could announc
second indic diagnost platform potenti guid earli proof-
of-concept data on-going trial preval cancer endometriosi
reiter outperform rate adjust pt previous reflect
believ triag asymptomat diagnost panel could
final late label ce mark support
valid studi asymptomat patient earli expect
product valid proceed rel quickli follow transit commercial-
grade reagent alter project nu us launch
confer call manag detail extens work involv
transit nu assay commercial-grad product rel
discovery-grad product commercial-grad reagent must adher strict
qualiti control well-character stabil shelf life
expect compani announc second indic nu
develop given compel recent data pilot trial prostat cancer
featur detect rate specif would surpris
volitionrx advanc diagnost prostat cancer diagnost develop
indic benefit test enrich sampl true
could see updat studi trial
conduct univers bonn evalu nu diagnost preval
cancer separ proof-of-concept trial explor nu endometriosi
on-going volit also recent announc pilot trial nu detect
anim cancer collabor texa
volitionrx report loss per share line estim
updat ep estim reflect updat develop timelin
nu program estim volitionrx cash posit
sustain oper includ addit
potenti exercis warrant associ compani august financ
volitionrx diagnost compani
focus develop blood
detect epigenet
signatur cancer
analyst certif import disclosur see disclosur
success valid studi support label eu
eu commerci launch
success edrn/nci valid studi us fda
approv us commerci launch
recommend medic societi uspstf
screen option non-compli subject
risk-adjust revenu approxim
higher anticip sale eu us non-
success commerci nu diagnost addit
nu adopt front-lin screen option elig adult
success product develop addit cancer
believ volit nu blood-bas diagnost
meaning improv gap screen complianc
colorect cancer valuat base primarili nu qs
market opportun screen us eu also
includ small contribut nu triag test select
potenti result screen sampl train studi
final nu panel use eu screen valid studi
potenti obtain ce mark launch eu
final nu panel us-focus screen valid studi
nu diagnost perform valid studi lower
failur obtain eu label claim and/or fda approv
support use non-compli subject
inabl nu obtain accept medic societi
guidelin uspstf limit commerci uptak
valu volit use averag revenu ep multipl analysi arriv price target appli multipl
risk-adjust revenu estim discount period appli multipl ep
estim discount period ad volit project cash per share round obtain
month price target
risk includ price clinic regulatori financ market competit
note view vnrx stock trade specul appropri risk-toler investor
nu asymptomat screen
potenti present result sampl train studi
potenti final nu panel use eu valid studi
potenti complet sampl valid studi support eu label
potenti obtain ce mark
potenti final nu panel us-focus valid studi sampl
nu triag
potenti final nu triag product panel
potenti obtain ce mark
nu symptomat screen
final regulatori strategi approv label claim us eu
compani present oppenheim co estim
valu volitionrx use discount earn per share revenu multipl
analysi current ascrib valu nu q-base product two colorect
cancer screen set front-lin screen non-compli us eu subject
triag set combin fecal-bas test select eu countri
also assum modest revenu stream sale research-us kit voltionrx
nu panel commerci partner activ motif believ
screen non-compli colorect cancer repres primari unmet medic
need address compani nu q-base product
given pre-commerci stage nu elect use high discount rate
risk-adjust anticip sale model po triag product
po non-triag set updat price target reflect updat timelin
nu triag screen test commerci eu estim
eu launch previous nu triag test eu launch previous
nu screen test continu estim us launch nu
screen test
profit molecular diagnost compani
histor trade within averag sale multipl rang averag
ep multipl rang valu volit use revenu ep multipl
analysi appli multipl risk-adjust revenu estim
discount period obtain target price appli
multipl ep estim discount period
obtain target price averag result two method ad
project cash per share obtain month price target round
exhibit valuat sensit analysi
sec file oppenheim co research
figur thousand except per share revenu nu us sale european sale good sold expens research develop gener administr sale oper loss incom incom expens interest loss incom incom incom loss comprehens loss gain foreign currenc translat comprehens incom loss per share share outstand co inc mark breidenbach volitionrx limit
sec file oppenheim co research
figur cash current current equip asset director fee portion long term portion capit leas grant incomecurr portion grant current leas equitycommon paid-in comprehens stockhold liabil stockhold co inc mark breidenbach vnrx outperform
stock price compani mention report
